This is mind blowing. A recently published study showed an impressive 28.7% weight loss in participants over 68 weeks using a new drug called retaretide. It even brought great relief from knee arthritis pain. But when you hear about amazing results like these, your first thought is: What’s the point? What’s the downside?
In the world of medicine, especially with powerful new drugs, there is always a trade-off. Today, we’re going to dive into Retatrutide. We’ll take a look at the amazing science behind how it works, compare its results to other popular weight loss drugs you’ve heard about, and most importantly, reveal potential risks and side effects that don’t make the headlines. You need to have the full picture before you get excited about this new option. (Based on the experience of Dr. Brad Stanfield)
Key takeaways
- What is it: Retatrotide is a new “triple agonist” injectable drug. It targets three different hormone receptors in your body (GLP-1, GIP, and glucagon) to promote weight loss and suppress appetite.
- Results: In one large study, participants taking the highest dose lost an average of 28.7% of their body weight — a staggering 71 pounds for the average person in the trial.
- Comparison: On the surface, the weight loss effects appear to be significantly superior to existing medications e.g Ozimbek (which saw about a 15% weight loss in their trial) and Mounjaro (about a 21% weight loss).
- hunting: The medication comes with a much higher rate of side effects. The dropout rate from the study was alarmingly high, and approximately 21% of participants developed a painful nerve-related condition called dysesthesia.
- Verdict: While the weight loss numbers are impressive, the troubling side effect profile suggests that the additional benefits currently may not outweigh the additional risks compared to other available options.
1. What is retaretide? “Triple riser,” he explained.
You’ve probably heard about the new class of weight-loss drugs that have become household names. To understand what makes Retatrutide so unique, you first need to understand how other medications work. It all started with GLP-1.
GLP-1 (glucagon-like peptide-1): This is the primary goal and mechanism behind drugs like Ozempic and Wegovy. GLP-1 is a natural hormone that your body secretes when you eat. It tells your pancreas to release insulin, slows how quickly your stomach empties (making you feel full), and acts on your brain to suppress appetite and reduce cravings. The innovation was to create a synthetic version that would last a week instead of just a few minutes.
GIP (Gastrointestinal Inhibitory Peptide): This is the second goal. Scientists wondered what they could add to GLP-1 to get better results. They switched to GIP, another hormone that also helps release insulin. By creating a drug that hits both GLP-1 and GIP receptors, they created Mounjaro (Tirzepatide), which has shown greater weight loss than GLP-1 drugs alone.
Glucagon: This is where Retatrutide takes a revolutionary leap forward. He adds a third target: the glucagon receptor. This is a bit counterintuitive because glucagon’s main job is to raise blood sugar by telling the liver to release glucose. However, it also has some very attractive weight loss effects: it can boost your metabolism (energy expenditure), stimulate the breakdown of stored fat, and prevent the formation of new fat. The theory behind Retatrutide is that by combining a glucagon agonist with its powerful GLP-1 and GIP effects, you can get the fat-burning benefits of glucagon while negating its blood sugar-raising effects. It is a three-pronged attack designed for maximum effect.
2. Amazing study results: weight loss and pain relief
So the theory of the 3D approach is compelling, but does it work in the real world? The results of the recent phase III trial are what is causing all the hype. The study looked at 445 adults who were overweight or obese. The key detail is that these participants did not have diabetes, but they did suffer from knee osteoarthritis.
Over the course of 68 weeks, the results were amazing. Let’s break it down:
- Weight loss: The group taking the higher dose of retareotide lost an average of 100% of weight loss 28.7% of starting body weight. For the average participant, this was a loss of 32 kilograms, or about 71 pounds. The lower dose was almost as effective, resulting in a 26.4% weight loss. By comparison, the placebo group lost only 2.1% of their body weight.
- Pain relief: Because the participants had knee arthritis, the researchers also measured their pain levels. In both retaretide groups, reported pain levels decreased by an incredible 75%. While the placebo group also saw a 40% reduction (the placebo effect is very real, especially for pain), the effect of retaretide was much greater.
These numbers are undoubtedly the most impressive we have ever seen from a weight-loss drug in a clinical trial.
3. Retrotide vs. the competition: a new champion?
To put this 28.7% figure into perspective, you have to compare it to other major players in the market. When you line them up, Retatrutide seems to be in a league of its own.
- Ozempic/Wejovi (Semaglutide): In its main trial of weight loss in non-diabetic individuals, participants lost about 20% of weight 15% of body weight over a similar period of time.
- Mongaro/Zebond (Terzipatide): In its landmark trial, the dual-agonist drug resulted in weight loss at a rate of approx 21% at its highest dose.
So you have 15% for the single riser, 21% for the double riser, and now 29% for the triple riser. The progress is clear: each new target adds another layer of efficacy, pushing the boundaries of what is possible with pharmacological weight loss. On the surface, Retatrotide looks like the new undisputed king of the hill.
4. Warning signs: File for troublesome side effects
This is where we have to pump the brakes. These headline numbers are eye-catching, but when you dig into the data, you find some serious reasons for caution. The first major red flag is the dropout rate.
amazing 18% Participants who took the higher dose of retaretide withdrew from the study before completion. To put that in perspective, the dropout rate in the Ozimbek trial was 4.5%, and in the Mongaro trial, it was just over 7%. A dropout rate of 18% is very high and indicates that the experience of taking the medication was unbearable for approximately one in five people.
The study authors suggest that this is because people with a low BMI dropped out of the study after losing “too much weight.” But even if you only look at people with higher BMIs, the rate is still over 12%, which is much higher than its competitors. This high rate is likely driven by adverse effects.
All of these medications share common side effects such as nausea and diarrhea. When using Retatrutide, about 35% of participants reported diarrhea, compared to 23% when using Mounjaro. But the most worrying side effect is one that is very rare with other medicines: Dysesthesia. This is a neurological condition where you feel unpleasant sensations such as pain, itching, burning or tingling when you touch your skin. In Mongaro studies, only 0.4% of people reported this. In the retaretide study, approximately 21% of people who took a high dose reported it. Although the researchers said the symptoms were mild, this is a huge red flag that needs serious investigation.
5. Statistical sleight of hand? Why is 29% not the whole story?
There are other important details buried in the study’s initial report. The 28.7% weight loss figure comes from what is called an “effectiveness estimate.” This analysis essentially shows the best-case scenario, where the drug effect is estimated if everyone followed the study protocol perfectly and no one dropped out of the study.
However, a more realistic measure is “treatment regimen estimation” (also known as intention-to-treat analysis). This includes everyone who started the study, which gives a better picture of the real-world impact. When you look at that number for Retatrutide, the average weight loss at the highest dose was 23.7%.
Now, let’s compare that to the real Mongaro number, which was 20.9%. Suddenly, the huge gap between the two properties shrinks dramatically. The difference is no longer a huge 8 percentage points (29% vs. 21%), but is much smaller at 2.8 percentage points (23.7% vs. 20.9%).
My opinion: Is retatrotide worth the risk?
So, let’s go back to our original question. What’s the point? What’s important is that you’re trading a much higher risk of side effects — including a 1 in 5 chance of developing a painful skin condition — for a potential 3% additional weight loss compared to the next best option.
For most people, this is not a good trade-off. Until we have more long-term safety data, I would not consider retaretide a first-line option compared to a drug like Mongaro/Zipound (terzebatide), which seems to have a much better balance between efficacy and tolerability.
Retatrotide may eventually find its place as an option for people who don’t achieve their goals with other medications and are willing to accept the higher risks. But for now, it’s a powerful tool with some very sharp edges.
conclusion
Retatrotide represents the latest science in weight loss, and its power is undeniable. However, power always comes with responsibility and risk. The headlines scream about a 29% weight loss, but the full story is much more complicated. They involve side effects, high dropout rates, and minute statistics. Although it is an exciting development to watch, the best approach at the moment is cautious optimism. We will have to wait for the full peer-reviewed data to be published before we can truly know whether the benefits of this powerful new drug outweigh its significant costs.
source: Dr. Brad Stanfield
